News stories about Minerva Neurosciences (NASDAQ:NERV) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Minerva Neurosciences earned a news impact score of 0.16 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.342071318987 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

A number of analysts recently commented on NERV shares. ValuEngine cut Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a research report on Monday, May 29th. JMP Securities reiterated an “outperform” rating and set a $20.00 price objective (up previously from $17.00) on shares of Minerva Neurosciences in a research report on Thursday, June 1st. BidaskClub cut Minerva Neurosciences from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Zacks Investment Research upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a research report on Wednesday, August 9th. Finally, Citigroup Inc. started coverage on Minerva Neurosciences in a research report on Friday, September 1st. They set a “buy” rating and a $11.00 price objective for the company. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $13.94.

Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.07. During the same period in the previous year, the company earned ($0.18) EPS.

COPYRIGHT VIOLATION WARNING: “Minerva Neurosciences (NERV) Receiving Somewhat Positive Press Coverage, Study Shows” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

Insider Buying and Selling by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.